 2
 
 
ੱխࣝࣝभޑ໒วǺவΓᜪ೷Ո༸ಒझ຾ՉᐋँރಒझᡏѦคՈమቚ෗ᇨᏤמೌϐࣴว 
Whole process in the serum-free condition for large generation of dendritic cells from human 
hematopoietic stem cells 
 
ीฝጓဦǺNSC 98ɡ2221ɡEɡ155ɡ072 
 
୺Չයज़Ǻ98ԃ 8Д 1ВԿ 99ԃ 7Д 31В 
Ь!  ࡭!  ΓǺ࠴Ͽঐ ϡඵεᏢϯᏢπำᆶ׷਑ࣽᏢᏢسȐ܌ȑ 
Ӆӕ  Ь࡭ΓǺ໳ਏ҇   १ࠔπ཰ว৖ࣴز܌ 
ीฝୖᆶΓ঩Ǻ၏Ӏӹ ϡඵεᏢϯᏢπำᆶ׷਑ࣽᏢᏢسȐ܌ȑ 
  
΋. ύЎᄔा 
ӧΓᡏύǴᐋँރಒझ(dendritic cells)җ೷Ո༸ಒझϩϯԶٰǴڀԖտᏘဍዦಒझ܈ࢂಒझѦੰচ
ᡏǴ٠ஒ੝ۓלচև౜ܭಒझጢ߄य़΢Ǵаٮ T ಒझ຾Չᒣ᛽ޑૈΚǴࢂфૈനமεޑלচև౜ಒझ
(antigen presenting cells)Ǵӧխࣝس಍ύתᄽख़ाޑفՅǶᐋँރಒझ཮߄౜εໆޑ class II MHCלচ
ᆶӭᅿޑ֎ߕϩη(adhesion molecules)ǴхࡴΑ CD11aǵCD11cǵCD50ǵCD54ǵCD58ᆶ CD102ǶԜ
ѦǴCD86཮߄౜ӧԐයޑᐋँރಒझǴԶ CD80ǵCD83ᆶ CMRF-44߾཮߄౜ӧԋዕޑᐋँރಒझǶ  
౜Ϟᕎੱޑᕍݤх֖ѦࣽЋೌǵϯᏢݯᕍᆶܫ৔ݯᕍǴՠคፕՖᅿᕍݤჹ஻ޣ֡Ԗ๱ᝄख़ୋբҔǴ
Ъೌࡕൺว܄ཱུଯǶ߈ٰᑈཱུว৖ޑཥᕍݤࣁխࣝᕍݤǴځύа౽෌ᐋँރಒझٰ௴୏Ь୏խࣝس಍Ǵ
຾ԶڈᐟరЃಒझ(Ьाࣁ T ಒझ)ౢғלဍዦޑਏ݀ǴࢂҞ߻խࣝᕍݤޑख़ाᖿ༈Ǵᖏ׉΢ΨԖ೚ӭ
зΓයࡑޑ่݀ǶฅԶᐋँރಒझ౽෌܌य़ᖏډޑ౟ᓍӧܭ౽෌܌ሡޑಒझኧໆόىǴЪੰ஻Ծᡏᐋ
ँރಒझޑғ౛фૈ܄ҭό٫ǴᏤठ౽෌Ѩ௳ǶԜѦǴᖏ׉΢ว౜Ǵੰ஻ӧ౽෌ࡕᕎੱൺวޑᐒ౗ᆶ
ᐋँރಒझ౽෌ޑኧໆԖᜢǴӢԜࡌҥԾฅఠЋಒझᡏѦεໆቚ෗ᆶᇨᏤޑБݤǴЪගଯځғ౛ࢲ܄Ǵ
ߡԋࣁᖏ׉΢ಒझխࣝݯᕍޑख़ाፐᚒǶ 
ҁჴᡍ࠻ςࡌҥ೷Ո༸ಒझᡏѦคՈమቚ෗מೌǴ಄ӝፁғݤೕکᖏ׉၂ᡍϐወΚǴӕਔς᛾ჴ
၀คՈమቚ෗ϐ೷Ո༸ಒझё຾΋؁೏஑΋ᇨᏤࣁӭᅿԋዕޑՈనಒझ(хࡴԾฅఠЋಒझǵՈλ݈߻
០ಒझᆶѮᏘಒझ฻)Ǵ٠߃؁᛾ჴڀԖϩϯࣁᐋँރಒझޑወΚǶӢԜҁࣴزीฝޑҞޑࣁ໒วрന
፾ϯϐᐋँރಒझቚ෗ᇨᏤ୻Ꭶس಍ǴаౢғεໆڀԖ҅ዴғ౛фૈޑᐋँރಒझǶ 
 
 
Abstract 
Human dendritic cells (DCs) are differentiated from hematopoietic stem cells (HSCs) and are unique and 
professional antigen-presenting cells (APCs), since the principal function of DCs is to uptake pathogens and 
tumor cells, present specific antigens on the cell surface, and induce a primary immune response in T cells. 
Thus, DCs play an important role in the immune system. DCs express large amounts of class II MHC antigen 
and a variety of adhesion molecules including CD11a, CD11c, CD50, CD54, CD58 and CD102. Besides, 
CD86 tends to be a marker of early DC maturation, while CD80, CD83 and CMRF-44 only appears in mature 
DCs. 
 4
܈ࢂಒझѦੰচᡏ(ٯӵಒ๵ᆶ༾ғނ฻)Ǵ٠ஒ੝ۓלচև౜ܭಒझጢ߄य़΢Ǵаٮ T ಒझ຾Չᒣ᛽
ޑಒझǶځύᐋँރಒझࢂҞ߻ࣴزύว౜фૈനࣁமεޑלচև౜ಒझǴૈ୼ᙖҗלচޑ߄౜ٰᇨ
วࡕϺ፾ᔈ܄խࣝϸᔈǴᐋँރಒझΨࢂനख़ाޑלচև౜ಒझǴӢࣁѝԖᐋँރಒझૈ୼௴୏Ҷ઀
ύޑ naðve T lymphocytesٰ຾Չ primary immune responseǶࣁΑ߄౜΢ॊޑфૈǴᐋँރಒझڀԖૈ
୼ਂᕇלচǵೀ౛לচ٠ஒځ፾྽ޑלচڈᐟϩηև౜ӧಒझጢ߄य़ޑૈΚǴ٠Ъӧᆢ࡭ Bಒझࢲ܄
ᆶ௴୏૶Ꮻ܄խࣝϸᔈ(recall response)΢תᄽ๱ख़ाޑفՅǶᆕԶقϐǴᐋँރಒझתᄽ๱ගܹխࣝಒ
झᒣ᛽ᆶࢥఠૈΚޑفՅǴᖏ׉΢߾ёၮҔᐋँރಒझޑғ౛੝܄Ǵ຾Չᐋँރಒझޑ౽෌Ǵٰቚ຾
ᕎੱݯᕍޑਏ݀ǶฅԶҞ߻ӧᖏ׉΢ᐋँރಒझޑᔈҔ܌य़ᖏޑനε౟ᓍࣁவԾᡏ܈ਈᜄޣي΢܌ԏ
໣ޑᐋँރಒझኧໆόىǴӢԜ໒วΓᜪᐋँރಒझޑᡏѦቚ෗ᇨᏤ୻Ꭶس಍ჴΏ྽୍ϐ࡚ǶԜѦǴ
ӧѸ໪಄ӝ cGMP ᆶ cGTP ೕጄޑा؃ΠǴࡌᄬؒԖ୏ނٰྍނ፦ᆶؒԖՈమబуޑᐋँރಒझᡏѦ
ቚ෗ᇨᏤ୻Ꭶ୷ࢂ΋ঁॶளࡷᏯޑ᝼ᚒǶ 
ҁჴᡍ࠻ςԋф໒วр೷Ո༸ಒझᡏѦคՈమቚ෗୻Ꭶس಍ǴёаӧᡏѦคՈమޑచҹΠǴܭ΋
ঁᘶࡨϣεໆቚ෗೷Ո༸ಒझၲ 30७ǴЪς࿶ࡌҥεໆᇨᏤࣁԾฅఠЋಒझ(΋ঁДϣёаቚу 25,000
७) ᆶՈλ݈߻០ಒझ(΋ঁᘶࡨϣёаቚу 5,000७)ޑᇨᏤس಍Ƕ୷ܭӃ߻ޑჴᡍ࿶ᡍǴ᛾ჴ่ӝ೷
Ո༸ಒझቚ෗୻Ꭶس಍ᆶ੝ۓಒझᇨᏤس಍ǴёаౢғεໆڀԖфૈ܄ޑԋዕՈనಒझǴӢԜҁය୯
ࣽ཮ीฝҙፎޑҞޑǴ׆ఈૈࡌҥᐋँރಒझޑคՈమቚ෗ᇨᏤس಍Ǵ٠่ӝӃ߻ҁჴᡍ࠻܌ֹԋ໒
วޑ೷Ո༸ಒझคՈమቚ෗س಍Ǵ٬ੰΓёа٬ҔԾᡏ܈ࢂ࿶җ౦ᡏଛჹ܌ளډޑ೷Ո༸ಒझǴ࿶ᡏ
Ѧεໆቚ෗୻ᎦࡕǴӆ຾΋؁ᇨᏤࣁᐋँރಒझǴӕਔӆ่ӝ 95-97ԃࡋҁΓ୯ࣽ཮ीฝޑԋ݀-Ծฅ
ఠЋಒझޑคՈమቚ෗ᇨᏤس಍ǴӕਔஒεໆᇨᏤ܌ளޑᐋँރಒझаϷԾฅఠЋಒझ౽෌ӣੰΓᡏ
ϣ຾ՉխࣝᕍݤǴԜמೌӧᖏ׉΢ڀԖࡐεޑᔈҔወΚǴӕਔёаа൚ۓᐋँރಒझᆶԾฅఠЋಒझ
ӧխࣝᕍݤᆶځᔈҔ΢ޑ୷ᘵǴΨஒ཮ࢂ२ࡋࣴزᐋँރಒझᆶԾฅఠЋಒझҬϕբҔޑࣴزीฝǶ 
 
 
Ο. ࣴزБݤ 
1. Γᜪᙏ஥Ոൂਡಒझ(mononuclear cell, MNC)ޑᖼວǺ 
1.1. Γᜪᙏ஥Ոൂਡಒझ(mononuclear cell, MNC)ёவ stem cell technologyϦљᖼວǴ୯ϣࣁז
ᑫϦљж౛Ǵёᙁϯᙏ஥Ոనಒझڗளٰྍޑำׇᆶ࿶຤Ƕ 
1.2. ஒ܌ளϐMNCᝌੌܭMACS buffer (D-PBSɠ0.5% BSAɠ2 mM EDTA)аଞჹ੝ۓ߄य़לচ
ޑಒझ຾Չપϯޑ؁ᡯǶ 
2. CD133
+
 cellޑપϯǺ 
2.1. ஒಒझᝌੌӧMACS bufferύǴಒझஏࡋ (cell density)ɦ108 total cells/ 300 ͔lǶܭ؂ 108 total 
cellsύӃуΕ 100 ͔l FcR blocking reagentаᗉխ CD133 Microbeadsᆶځдᚇಒझ׎ԋߚ
੝ۓᗖ่ǶӆуΕ 100 ͔l CD133 MicrobeadsǴӧ 6-12кΠᗉӀϸᔈ 30 minǶ 
2.2. ϸᔈࡕճҔMACS bufferమࢱ೏኱ᇞޑಒझٿԛǴᚆЈǺ700 x gǴ5 minǶ٠ஒ೏኱ᇞޑಒ
झᝌੌܭ፾ໆޑMACS bufferύǶ 
2.3. ஒ magnetic column࿼ܭ஥Ԗᅶ൑ޑMiltenyi VarioMACS deviceύǴճҔMACS bufferమࢱ
columnٿԛ٠ߥ࡭ᔸዎǶӆஒ೏኱ᇞޑಒझ೯ၸ pre-filterᆶ columnǴௗ๱ҔMACS buffer
ஒ҂֎ߕӧᅶ൑ columnύޑಒझࢱрǶ 
 6
Cells/mLɨ͉0+͉1x1+͉2x2+͉3x3+͉4x4+͉5x5+….………+͉n xn  (1) 
ӣᘜ߯ኧޑ҅ॄᆶελёаҔٰ೛ीଥϲၡ৩Ǵ٠ղᘐ၀Ӣηჹᐋँރಒझቚ෗ϐቹៜǹ
ջӣᘜ߯ኧຫεǴቹៜຫεǴ҅ॶ߄ҢԖߦ຾ޑਏ݀ǴԶॄॶ߄ҢԖ׭ڋޑբҔǶଥϲၡ৩ࢂ
ਥᏵӣᘜ߯ኧޑ҅ॄᆶελٰቚу܈෧ϿӚԋϩబуޑᐚࡋǴа؃ளന፾ϯϐᐚࡋǴᙖԜ໒ว
рᐋँރಒझޑᡏѦന፾ϯᇨᏤቚ෗୻Ꭶ୷Ƕ 
 
Ѥ. ่݀ᆶ૸ፕ 
ҁीฝޑԋ݀ς࿶ֹԋ᏾౛Ǵ٠ྗഢ׫ዺύǴ׫ዺޑයтࣁCytotherapyǶ٠ஒ೽ϩ่݀ᙁॊӵΠǶ
ԜѦीฝ࣬ᜢ܌़ғϐځдԋ݀ǴፎୖԵ2009ԃ܌ว߄ޑ3ጇSCIЎകǶ 
 
ࣴزԋ݀Ǻ 
२ӃவΓᜪᙏ஥Ոύϩᚆрൂਡಒझ(mononuclear cells, MNCs)ǴϐࡕճҔMiltenyi VarioMACS 
deviceஒ CD133+೷Ո༸ಒझ(fresh hematopoietic stem cells, fresh HSCs)ϩᚆрٰǶϐࡕӆճҔҁჴᡍ
܌໒วϐคՈమ೷Ո༸ಒझቚ෗୻Ꭶ୷(SF-HSC୻Ꭶ୷)Ǵа 5 x 104 cells/mlޑಒझஏࡋ୻ᎦǴ຾Չ೷
Ո༸ಒझޑคՈమቚ෗Ƕ୻Ꭶ 7 ϺࡕǴёаளډεໆቚ෗ޑ೷Ո༸ಒझ (serum-free expanded 
hematopoietic stem cells, expanded HSCs)Ƕௗ๱ӆஒ fresh HSCsаϷ expanded HSCs຾Չ 9Ϻޑᐋँ
ރಒझ(dendritic cells, DCs)ᇨᏤ୻ᎦǴᇨᏤޑచҹࣁǺRPMI 1640 mediumϣబу 100 ng/mL granulocyte 
macrophage colony-stimulating factor (GM-CSF), 10 ng/mL tumor necrosis factor-alpha (TNF-"), 50 ng/mL 
stem cell factor (SCF)аϷ 10% AB human serumǴԜਔޑಒझᆀϐࣁ҂ԋዕᐋँރಒझ(immature 
dendritic cells, iDCs)Ǵ٠ᔠෳځלচ߄౜Ƕϐࡕӆஒ iDCs຾Չ 1ϺޑڈᐟᇨᏤǴаౢғԋዕޑᐋँރ
ಒझ(mature dendritic cells, mDCs)ǴᇨᏤԋዕޑచҹࣁǺRPMI 1640 mediumϣబу LPS (1ug/ml) аϷ
10% AB human serumǴ٠ᔠෳځלচ߄౜Ƕ 
ჴᡍ่݀ว౜வᙏ஥Ոనύϩᚆрϐ೷Ո༸ಒझ(fresh HSCs)Ǵ࿶ၸᇨᏤࡕǴڀԖϩϯࣁ҂ԋዕᐋ
ँރಒझ(iDCs)ޑૈΚǴӕਔӆ຾΋؁ޑ࿶ၸLPSޑڈᐟǴёаԋࣁԋዕޑᐋँރಒझ(mDCs)ǶᇨᏤࡕ
܌ౢғϐ҂ԋዕᆶԋዕޑᐋँރಒझ֡߄౜CD14 (18-20%), CD1a (~5%), CD11c (7-11%)ᆶCD86 
(~17%)(Fig. 1)ǶԜѦவᙏ஥Ոనύϩᚆрϐ೷Ո༸ಒझ(fresh HSCs)ǴӃ࿶ၸคՈమޑቚ෗ࡕǴ܌ౢғ
рεໆޑ೷Ո༸ಒझ(expanded HSCs)Ǵӆ࿶ၸ࣬ӕ؁ᡯޑᇨᏤǴ᛾ჴexpanded HSCsόՠߥ࡭ԖԖϩϯ
ࣁ҂ԋዕᐋँރಒझ(iDCs)ᆶԋዕᐋँރಒझ(mDCs)ޑૈΚǴԶЪځϩϯࣁDCsޑКٯᆶኧໆ࣬ၨܭ
fresh HSCsԖ๱׳ܴᡉޑගϲǶᇨᏤࡕ܌ౢғϐ҂ԋዕᆶԋዕޑᐋँރಒझ֡߄౜CD14 (13-16%), 
CD1a (29-33%), CD11c (7-12%)ᆶCD86 (46-60%)ǴځύCD86߄౜ޑගϲനࣁܴᡉ(Fig. 2)Ƕҁࣴز߃؁
᛾ჴǴ࿶ၸคՈమεໆቚ෗ࡕޑ೷Ո༸ಒझǴڀԖ׳ଯޑࢲ܄Ǵёа຾΋؁೏ᇨᏤࣁڀԖфૈ܄ޑᐋ
ँރಒझǴ೭ஒԖշܭँઇҞ߻ᐋँރಒझӧխࣝݯᕍ΢ኧໆόىޑ౟ᓍǶҁࣴزҞ߻߾ᝩុරӛᐋ
ँރคՈమᇨᏤ୻Ꭶس಍ޑБӛ߻຾ǴႣीֹԋࡕǴ่ӝа໒วֹԋϐ೷Ո༸ಒझคՈమቚ෗୻Ꭶس
಍Ǵஒё໒วр಄ӝcGTPᖏ׉ᔈҔ኱ྗޑᐋँރಒझεໆᇨᏤ୻Ꭶس಍Ǵගϲ҂ٰᐋँރಒझӧխࣝ
ݯᕍ΢ޑᔈҔወΚǶ 
 
 8
12.Fong L., Dendritic cells in cancer immunotherapy. Annual Review of Immunology 2000;18:245-273. 
13.Hagihara M et al., Extensive and long-term ex vivo productiob of dendritic cells from CD34 positive 
imbilical cord blood or bone marrow cells by novel culture system using mouse stroma. Journal of 
Immunological Methods. 2001;253:45-55. 
14.Jiang XX et al., Human mesenchymal stem cells inhibit differentiation and function of 
monocyte-derived dendritic cells. Blood 2005;15:4120-4126. 
15.Lipscomb MF., Dendritic cells: Immune regulators in health and disease. Physiol Rev 
2002;130:82-97. 
16.Nguyen XD et al., Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction 
with dendritic cells. Journal of Immunological Methods. 2003;275:57-68. 
17.Nencioni A et al., Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells 
2004;22:501-513. 
18.Oki M et al., Efficinet lentiviral transduction of human cord blood CD34+ cells followed by their 
expansion and differentiation into dendritic cells. Experimental Hematology 2001;29:1210-1217. 
19.O’Neill HC et al., Dendritic cell development in long-term spleen stromal cultures. Stem Cells 
2004;22:475-486. 
20.Sato K et al., Generation of dendritic cells from fresh and frozen cord blood CD34+ cells. 
Cryobiology 1998;37:362-371. 
21.Strobl H et al., TGF-͊1 promotes in vitro development of dendritic cells from CD34+ hemopoietic 
progenitors. Journal of Immunology 1996;157:1499-1507. 
22.Syme R., Generation of dendritic cells: role of cytokines and potential clinical applications. 
Transfusion and Apheresis. Science 2001;24:117-124. 
23.Urbini B et al., Allogeneic graft CD34+ cell dose correlates with dendritic cell dose and clinical 
outcome, but not with dendritic cell reconstitution after transplant. Experimental Hematology 
2003;31:953-958. 
24.Chen TW
 
et al., Large Generation of Megakaryocytes from Serum-Free Expanded Human CD34
+
 
Cells. Biochemical and Biophysical Research Communications 2009;378:112-117. 
25.Chang CL et al., Lysophosphatidic acid-induced interleukin-1  expression is mediated through 
Gi/Rho and the generation of reactive oxygen species in macrophages. Journal of Biomedical 
Science 2008;15:357-363. 
26.Kao IT et al., Generation of Natural Killer Cells from Serum-free Expanded Human Umbilical Cord 
Blood CD34
+ 
Cells. Stem Cells and Development 2007;16:1043-1052. 
27.Yao CL et al., Characterization of serum-free ex vivo-expanded hematopoietic stem cells derived 
from human umbilical cord blood CD133
+
 cells. Stem Cells and Development 2006;15:70-80.  
28.Yao CL et al., Systematic strategy approach in medium design. Experimental Hematology 
2005;33:1273-1274. 
29.Yao CL et al., A systematic strategy to optimize ex vivo expansion medium for human hematopoietic 
stem cells derived from umbilical cord blood mononuclear cells. Experimental Hematology 
2004;32:720-727. 
30.Yao CL et al., Factorial designs combined with the steepest ascent method to optimize serum-free 
ߕҹΒ 
୯ࣽ཮ံշ஑ᚒࣴزीฝԋ݀ൔ֋Ծຑ߄!
ፎ൩ࣴزϣ৒ᆶচीฝ࣬಄ำࡋǵၲԋႣයҞ኱௃ݩǵࣴزԋ݀ϐᏢೌ܈ᔈҔሽ
ॶȐᙁा௶ॊԋ݀܌ж߄ϐཀကǵሽॶǵቹៜ܈຾΋؁ว৖ϐёૈ܄ȑǵࢂց፾
ӝӧᏢೌයтว߄܈ҙፎ஑ճǵЬाว౜܈ځдԖᜢሽॶ฻Ǵբ΋ᆕӝຑ՗Ƕ
1. ፎ൩ࣴزϣ৒ᆶচीฝ࣬಄ำࡋǵၲԋႣයҞ኱௃ݩբ΋ᆕӝຑ՗
Ɏ ၲԋҞ኱
ɍʳ ҂ၲԋҞ኱ȐፎᇥܴǴа 100ӷࣁज़ȑ
ɍʳჴᡍѨ௳!
ɍʳӢࡺჴᡍύᘐ
ɍʳځдচӢ
ᇥܴǺ
2. ࣴزԋ݀ӧᏢೌයтว߄܈ҙፎ஑ճ฻௃׎Ǻ
ፕЎǺɍςว߄!ɍ҂ว߄ϐЎዺ!Ɏኗቪύ!ɍค!
஑ճǺɍςᕇள!ɍҙፎύ!Ɏค!
מᙯǺɍςמᙯ!ɍࢳፋύ!Ɏค!
ځдǺȐа 100ӷࣁज़ȑ!
3. ፎ٩Ꮲೌԋ൩ǵמೌബཥǵޗ཮ቹៜ฻Бय़Ǵຑ՗ࣴزԋ݀ϐᏢೌ܈ᔈҔሽ
ॶȐᙁा௶ॊԋ݀܌ж߄ϐཀကǵሽॶǵቹៜ܈຾΋؁ว৖ϐёૈ܄ȑȐа
500ӷࣁज़ȑ
Ꮲೌԋ൩ᆶബཥǺჴᡍ่݀᛾ჴǴҁࣴزς࿶ޑ໒วр፾ӝᐋँރಒझܭᡏ
Ѧቚ෗୻Ꭶޑ୻Ꭶ୷Ƕჴᡍ२Ӄவᙏ஥Ոԏ໣໒ۈǴ຾Չ೷Ո༸ಒझ)DE45,
ಒझ*ޑϩᚆᆶપϯǴ٠࿶җҁ܌Ӄ߻܌໒วϐ೷Ո༸ಒझคՈమቚ෗୻Ꭶ୷
)TG.ITD*Ǵቚ෗೷Ո༸ಒझ΋ࢃයǶௗ๱ஒቚ෗ၸࡕޑ೷Ո༸ಒझճҔჴᡍ
೛ीᆶ಍ीϩ݋ޑБݤǴམଛ๱ଥϲၡ৩ന፾ϯಒझᐟનᐚࡋǴ᛾ჴቚ෗ၸ
ࡕޑ೷Ո༸ಒझڀԖ຾΋؁ϩϯࣁᐋँރಒझޑૈΚǴ٠Ъന፾ϯځ୻Ꭶ୷
ޑಔԋϷᐚࡋǶ!
ᔈҔሽॶǺ)2*!่ӝӃ߻໒วϐ೷Ո༸ಒझቚ෗ޑמೌǴу΢Ԗس಍ޑ೛ी
рᐋँރಒझᇨᏤ୻Ꭶ୷Ǵૈ୼Ԗਏޑεໆ୻ᎦрᐋँރಒझǶ)3*!եԋҁ
ޑଯѱ൑ᝡݾΚ)ಒझᐟનޑሽ਱ܳ຦ǴԶҁس಍ޑಒझᐟનଛБᐚࡋᇻեܭ
ѱय़΢ޑౢࠔ*ǴӵԜёаளډڀԖ࿶ᔮਏ੻ЪԋҁၨեޑᡏѦᐋँރಒझᇨ
Ꮴ୻Ꭶ୷Ƕ)4*!זೲޑᐋँރಒझᇨᏤמೌ׳Ԗճܭ҂ٰᖏ׉΢ޑ٬ҔǶ!

 10
 12
ȐमЎȑRecently, human dendritic cells (DCs) transplantation in 
immunotherapy was developed actively, and had great potential for 
cancer therapy. Therefore, it was an important clinical course to 
develop ex vivo expansion and induction system for DCs. 
In our laboratory, we have reported a serum-free and stroma-free 
medium (SF-HSC medium) for expanding HSCs. The SF-HSC 
medium was developed using a systematic and statistic methodology, 
and contained an optimal cytokine-limited cocktail formulation. The 
serum-free expanded cells have been proven that they had the ability 
to be differentiated into a variety of functional mature blood cells and 
showed that they maintained the ability to be differentiated into 
functional DCs in specific induction medium contained serum. The 
aim of this study is to develop a culture system for large production of 
functional DCs. We believe that the results of this study must be 
beneficial to the basic research and future trials on clinical 
transplantation. 
ౢ཰ձ!
ᙴᕍᏔ׷ᇙ೷཰!!
៝ୢ୍ܺ཰!!
ᛰࠔᔠᡍ཰!!
ࣴزว৖୍ܺ཰!!
ځд஑཰ǵࣽᏢϷמೌ୍ܺ཰!
מ 0ೌౢࠔᔈҔጄൎ! ᙴଣǵᙏ஥ՈϦљǵғמǵᇙᛰ཰ࣚ܈࣬ᜢࣴزൂՏǶ!
מೌ౽ᙯёՉ܄ϷႣය
ਏ੻!
୯ϣѦલЮԜᜪמೌ܈ౢࠔǴࡺౢࠔ໒วཱུڀѱ൑ወΚǴЪڀᖏ
׉ᔈҔϐወΚ!
!!!!!ຏǺҁ໨ࣴวԋ݀ऩۘ҂ҙፎ஑ճǴፎϮඟ៛ёҙፎ஑ճϐЬाϣ৒Ƕ!
!
!
!
!
!
!
!
 14
ک཮᝼࠻ǴӢԜѸ໪឴࣊௞೽ϩޑ᝼ᚒคݤӄำୖᆶǴࣗࣁёெǴՠࢂӧออޑѤϺϣǴ
ε཮Ѹ໪Ӽ௨ӵԜᚳεޑ཮᝼ᆶᆢ࡭᝼ำޑࢬᄣ܄ǴᗨࣁऍύόىϐೀǴՠჴΏόளа
ϐӼ௨ǶҁΓж߄ୖᆶԜԛ཮᝼Ǵ٠ว߄΋ጇੇൔፕЎǴᚒҞࣁ” Characterization and large 
generation of functional dendritic cells from serum free expanded human cord blood CD34
+ 
cells”ǴӧԜԛ཮᝼ύǴҁΓుགӚ୯֡ठΚܭಒझݯᕍᆶ౽෌ޑᖏ׉၂ᡍǴЀځࢂӧݯ
ᕍࡕӵՖቚу౽෌ԋф౗ᆶफ़եխࣝ௨ѾϸᔈǴ೴ᅌԋࣁࣴزЬࢬǴԜБय़ϐ຾৖ז
ೲǴԖձܭѠ᡼Ҟ߻ӧᖏ׉၂ᡍݤೕ΢ޑፏӭज़ڋǴԶףఠΑஒѠ᡼ፏӭ୷ᘵࣴزԋ݀
ᙯᡂԋჴሞᖏ׉ݯᕍޑว৖Ƕᕴ่ୖуҁԛ཮᝼ԏᛘཱུࣁᙦ൤Ǵό໻໒ܗ୯ሞຎഁǵᕕ
ှ୯ሞࣴزዊࢬǵ٠ᆶ೽ϩ୯ϣѦ๱ӜᏢޣԖ๱૸ፕᆶ჋၂ࡌҥӝբޑёૈ܄Ǵ࣬ߞჹ
ܭҁჴᡍ࠻౜ӧᆶ҂ٰ༸ಒझࣴزϐБӛᆶԋ݀௢ቶԖ๱ཱུεϐᔅշǶ 
!
Βǵᆶ཮Јள!
ҁΓୖуಃΖۛ International Society for Stem Cell Research Annual MeetingޑЬाҞޑ
ࣁǴԏ໣༸ಒझࣴزǵಒझ౽෌ǵխࣝݯᕍᆶ୷Ӣݯᕍϐനཥࣴزᖿ༈کനཥמೌϐԋ
݀ǶԜԛ཮᝼ନΑԖፏӭ୯ሞޕӜޑ༸ಒझᏢޣୖᆶѦǴќԖ೚ӭᖏ׉ᙴৣޑୖуǴӢ
ԜନΑૈᕇள༸ಒझࣴزޑཥޕѦǴ࣬ᜢޑᙴᏢᖏ׉ൔ֋ҭૈӭԖԏᛘǶ၀Ꮲ཮ԋҥޑ
ҞޑǴࢂԖ᠘ܭ߈ԃٰόፕಒझ౽෌ޑ୷ᘵࣴزᆶᖏ׉၂ᡍ֡Ԗᛈࣆ܄ޑว৖ǴӢԜ׆
ఈ่ӝШࣚӚ୯ౢǵ۔ǵᏢǵࣴޑӕӳӅӕಔԋ၀Ꮲ཮Ǵаගٮၠ୯ࣚޑ૸ፕ୔Ǵࡌҥ
ಒझݯᕍ߻ǵύǵࡕࢤޑ኱ྗೀ౛ำׇǴ٠ϩ٦Ӛ୯ᖏ׉၂ᡍޑ࿶ᡍǴаၲډ୯ሞҬࢬ
ᆶӝբޑҞޑǴ၀Ꮲ཮Ьा௖૸ᆶ఼ᇂޑጄൎх֖Αಒझޑ୷ᘵࣴزǵಒझݯᕍޑำ
ׇǵಒझᡏѦޑᏹբᆶᖏ׉౽෌ෳ၂฻Ƕ၀Ꮲ཮٠ԖวՉԖ୯ሞࣽᏢයтǺCell Stem 
 16
2. Ծᡏխࣝ੯ੰ(autoimmune diseases)Ǻ 
ӧԾᡏխࣝ੯ੰޑЬᚒ૸ፕύǴЬाԖΟঁᚒҞ຾Չ૸ፕǴځᚒҞᆶϣ৒ϩձ᏾౛ӵΠǺ 
(1) Mesenchymal stem cells treat EAE through a dual effect on inflammation and tissue 
damage 
(2) Marrow stromal cells as conditional antigen presenting cells 
(3) Novel immunomodulation strategies for children with resistant autoimmune diseases 
໔ယ༸ಒझ(mesenchymal stem cells)ࢂ΋ဂٰԾΓᡏମᡎ฻ӭೀёளϐԋᡏ༸ಒ
झǴڀԖϩϯԋମᓝǵ೬ମᆶિެ฻ૈΚǴ߈ٰҭԖЎ᝘ൔᏤǴ໔ယ༸ಒझૈ୼ϩϯԋ
ઓ࿶س಍Ǵ຾΋؁ගܹ໔ယ༸ಒझӧಔᙃঅൺᆶಒझݯᕍ΢ޑᔈҔጄൎǶനཥޑࣴزൔ
֋ࡰрǴ໔ယ༸ಒझନΑ΢ॊޑϩϯૈΚѦǴӧ୏ނᡏѦᆶᡏϣޑჴᡍύࣣว౜Ǵ໔ယ
༸ಒझૈᆶ Tಒझ܈ࢂ BಒझϸᔈǴ຾Զፓ࿯ғނᡏϣޑխࣝϸᔈǴٰၲډݯᕍԾᡏխ
ࣝ܄੯ੰ܈ࢂफ़ե౽෌ࡕխࣝ௨ѾϸᔈǶA. Uccelliი໗аڂࠠޑԾᡏխࣝ܄੯ੰ-တૉ
ᡎݹ(autoimmune encephalomyelitis)ࣁࣴزჹຝǴว౜ӧኳᔕ஻ԖတૉᡎݹޑԴႵύ౽෌
Ε໔ယ༸ಒझࡕǴନΑૈ୼फ़եวݹϸᔈޑጄൎѦǴ׳ૈ୼෧጗խࣝس಍ჹઓ࿶س಍ޑ
װᔐǴаᗉխᡎᓋ࡭ុޑಥပаϷቚу᏾ঁઓ࿶س಍ಒझޑኧໆǴၲډݯᕍတૉᡎݹޑ
ਏ݀ǶJ. Galipeauი໗߾ӧᡏѦჴᡍว౜ǴӧӸӧԖ໔ယ༸ಒझޑచҹΠǴ཮Ԗፓ࿯ T
ಒझޑғߏǵ׭ڋ Bಒझфૈᆶߦ຾ᐋँރಒझԋዕޑ่݀ǹ٠Ъว౜ӧబу interferon 
gammaޑ௃ݩΠǴ໔ယ༸ಒझ཮߄౜MHC class I & IIޑלচǴ຾Զፓ࿯ᆶ Tಒझ໔ޑ
բҔǴځՉࣁ߄౜ᜪ՟לচև౜ಒझ(antigen presenting cells)Ǵ၀ი໗ᇡࣁ໔ယ༸ಒझё
ૈ཮ࢂќ΋ᅿלচև౜ಒझǶN. Wulffraat ޑი໗߾ଞჹ஻ԖԾว܄ᜢ࿯ݹ(Juvenile 
idiopathic arthritis, JIV)ޑ஻ޣ຾ՉჴᡍǴ྽΋૓ݯᕍ JIV ޑᛰނ (ٯӵǺ
methylprednisoloneǵmethotrexateǵcyclophosphamide܈ࢂ anti TNF-alpha receptor)คਏਔǴ
཮Եቾჹ஻ޣ຾ՉԾᡏମᡎ༸ಒझޑ౽෌Ǵฅࡕӧ౽෌ၸำύ܌Їวޑ௨Ѿϸᔈத཮೷
 18
ڙᡏޑ߄౜Ǵٯӵ CCR5܈ࢂ CXCR4Ǵٰߔᘐ HIVੰࢥӧΓᡏϣޑᘉණ೼৩ǹ(3) ࿶ၸ
ੰࢥᙯࢉࡕޑ೷Ո༸ಒझғ౛܄፦ޑׯᡂǹ(4) ஒᕎੱלচޑڙᡏᙯࢉΕ T ಒझύǴቚ
у Tಒझᒣ᛽ᕎੱಒझޑૈΚ฻Ƕ 
 
4. ໔፦ಒझޑٰྍ(Alternative sources for stromal cells)Ǻ 
ӧ Stromal cellsޑځдٰྍޑЬᚒ૸ፕύǴЬाԖѤঁᚒҞ຾Չ૸ፕǴځᚒҞᆶϣ৒ϩ
ձ᏾౛ӵΠǺ 
(1) Human umbilical cord perivascular cells (HUCPVCs): a high yield source of MSCs 
(2) Unrestricted somatic stem cells (USSC) from cord blood: characterization, 
differentiation potential and hematopoiesis supporting activity 
(3) Adipose-derived stem cells 
(4) Alternative sources of Human SCs: Placenta-derived multipotent cells 
ମᡎύ֖Ԗᙦ൤ޑ໔ယ༸ಒझǴڀԖϩϯࣁମᓝǵ೬ମǵિެᆶԼԺޑૈΚǴԶЪ
ӧମᡎύࡌҥଆ፾ӝ೷Ո༸ಒझғߏޑ༾ᕉნǴ܌аΞᆀࣁ໔፦ಒझǶ߈ԃٰޑࣴزว
౜ǴନΑӧମᡎύǴΓᡏځޑᏔ۔ಔᙃύΨૈว౜ࣔ຦ޑ໔ယ༸ಒझޑᙫၞǴε൯ޑග
ܹ໔ယ༸ಒझޑᔈҔ܄Ǵ೭ঁ᝼ำ૸ፕޑЬᚒǴߡࢂ௖૸Ӛಔᙃύ܌ว౜໔ယ༸ಒझޑ
੝܄ǶJ. Daviesޑࣴزი໗ӧᙏ஥ڬൎޑՈᆅಔᙃύϩᚆр HUCPVCs (human umbilical 
cord perivascular cells)Ǵϐࡕว౜၀ಒझᆶ໔ယ༸ಒझԖ๱࣬೯ޑ੝܄Ǵځ߄य़לচޑ߄
౜ࣁ CD45-ǵCD34-ǵSH-2+ǵSH-3+ǵThy-1+ǵCD44+ǵTelomerase-ǵ3G5+ǵOct4-ᆶ CK8/18+Ǵ
ԶЪڀԖϩϯࣁ೬ମǵฯମᆶિެޑૈΚǴзΓᡋ೗ޑࢂ၀ಒझ׎ԋ CFU-FޑૈΚᇻଯ
ܭவମᡎ܈ࢂᙏ஥ՈύϩᚆрޑಒझǴ᛾ܴᙏ஥ՈᆅڬൎԖ๱ଯౢໆޑ໔ယ༸ಒझǶӧ
G. Koegler ޑი໗ύ߾ࢂவᙏ஥Ոύϩᚆύ໔ယ༸ಒझǴନΑёϩϯࣁ೬ମǵฯମᆶિ
ެѦǴۘڀԖϩϯࣁઓ࿶ǵી᠌ᆶط᠌ޑૈΚǴόၸ೭٤ၠखቫޑϩϯૈΚѸ໪ӧ੝ۓ
ޑᡏѦ୻ᎦచҹΠǴБૈၲԋǶJ. Gimbleޑი໗߾ࢂӧિެύϩᚆр໔ယ༸ಒझǴӧܜ
 20
኱ǴٯӵǺAldehyde Dehydrogenase (ALDH)ޑ߄౜Ǵёբࣁ׳ᆒዴႣෳೌࡕՈనύқՈ
ౚࡠൺޑࡰ኱ǴԶ CD34+CD110+ಒझ߾ёբࣁೌࡕՈλ݈ࡠൺޑࡰ኱฻Ǵёٮ҂ٰᖏ׉
౽෌΢׳ԖΚޑႣෳࡰ኱Ƕ 
 
Ꮫൔ৖ҢϐЈளǺҁԛε཮ӅԖຬၸ 500ጇа΢ޑᏛൔፕЎǴჴᜤ΋΋ݒ፞ǶӅϩࣁϤ
εЬᚒǺ(1)Cell and tissue evaluationǹ(2)Gene therapyǹ(3)Hematopoietic stem cellsǹ
(4)Immunotherapy and dendritic cellsǹ(5)Lab practices and legal and regulatory affairsǹ
(6)Non hematopoietic and mesenchymal stem cellsǶፕЎᏛൔϐ৖Ңϣ৒Ǵ࣬྽ޑӭኬᆶ
ཥᑉǴᗨฅ೚ӭࣁၨόֹ᏾܈ࢂ҂ԋዕޑኧᏵǴՠё࣮р೚ӭ౜Ϟࣴزϐᖿ༈کബཥϐ
གྷݤǶךӧԜ཮൑Ψว߄΋ጇᏛൔፕЎǴᚒҞࣁ” Characterization and large generation of 
functional dendritic cells from serum free expanded human cord blood CD34
+ 
cells”Ǵ৖Ңය
໔Ԗ೚ӭᆶ཮Γγჹךॺޑว߄Ԗᑫ፪Ǵ຾ԶԖ܌૸ፕǶ 
!
ΟǵԵჸୖᢀࢲ୏)คࢂ໨ࢲ୏ޣౣ*!
ค!
!
Ѥǵࡌ᝼!
ୖᆶ೭ԛޑࣴ૸཮Ǵགڙډ୯ሞ໔༸ಒझࣴزᆶಒझݯᕍޑሦୱ֡ࢂጲࠁޑว৖ǴѠ᡼
ᆶ୯ሞӚ୯࣬КǴঁΓభـᇡࣁӧ୷ᘵࣴزБय़Ǵځჴۘ҂ပࡕϼӭǴࣗԿӧࢌ٤੝ۓ
ޑሦୱύǴࢂೀܭሦӃޑӦՏǴฅԶ຾΋؁ஒࣴزޑԋ݀ᙯ౽ډჴሞޑᖏ׉ᔈҔ΢Ǵӧ
Ԝᗺ߾ࢂε൯ޑပࡕܭ୯ሞޑว৖Ǵ܈೚ࢂд୯ࣴزޣၨࣁᑈཱུҭ܈೚ࢂѠ᡼ݤೕӧΓ
 22
Characterization and large generation of functional dendritic cells from serum free expanded human 
cord blood CD34
+
 cells  
 
Chao-Ling Yao
1
, Shu-Ching Hsu
2
, Shiaw-Min Hwang
3
 
 
1
Department of Chemical Engineering and Materials Science, Yuan Ze University, Chung-Li city, 
Taiwan,  
2
Vaccine Research and Development Center, National Health Research Institutes, Miaoli County, 
Taiwan,  
3
Bioresource Collection and Research Center, Food Industry Research and Development Institute, 
Hsinch, Taiwan 
 
ABSTRACT 
The current therapies for cancer patients, including surgical operation, chemotherapy, or radiotherapy, were 
always followed with heavy side affect, and had high possibility to relapse. In human, dendritic cells (DCs) 
are differentiated from hematopoietic stem cells (HSCs), and are professional antigen-presenting cells (APCs). 
Thus, DCs play an important role in the immune system. Recently, DC transplantation in immunotherapy is 
developing actively, and has great potential for cancer therapy. However, DCs in the cancer patients had lower 
level than in normal, and lost their function against cancer cells. In clinical results, the amounts of DCs that 
transplanted into cancer patients were the crucial role to prevent cancer relapse. Therefore, it is an important 
clinical course to develop ex vivo large expansion and specific induction culture system for DCs. 
In our laboratory, we have developed a serum-free and stroma-free medium (SF-HSC medium) for expanding 
HSCs. In this study, the serum-free expanded HSCs have been further proven that they had the ability to be 
differentiated into functional DCs in specific induction medium. After 9-day induction in the RPMI 1640 
containing 100 ng/mL GM-CSF, 10 ng/mL TNF- , 50 ng/mL SCF and 10% AB human serum, immature DCs 
(iDCs) can be induced specifically and express CD1a, CD11c, CD14 and CD86. Then after lysophophatidic 
acid treated for one more day, the iDCs would become mature DCs (mDCs) and the CD86 expression would 
increase significantly. 
These results indicated that DCs derived from the serum-free expanded HSCs exhibited both characteristics 
and functions of DCs. Furthermore, the serum-free expanded HSCs showed a significantly higher DCs 
differentiation potential than freshly isolated HSCs, and DCs induced from serum-free expanded HSCs 
showed higher CD86 expression than those from freshly isolated HSCs. Therefore, combination of DC 
induction process and HSC expansion process can induce and expand a large amount of functional DCs 
efficiently, and might be a promising source of DCs for immunotherapy in the future. 
 
 
Keywords: umbilical cord blood, hematopoietic stem cell, dendritic cells, immunotherapy, ex vivo expansion 
 
This work was supported by Grant (98-2221-E-155-072) from the National Science Council, Taiwan. 
!
!
!
!
!
୯ࣽ཮ံշ஑ᚒࣴزीฝ໨Πрৢ୯ሞᏢೌ཮᝼Јளൔ֋!
! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !ВයǺ!::!ԃ!8!Д!8!В!
ीฝጓဦ! NSC! 98ɡ2221ɡEɡ155ɡ072 
ीฝӜᆀ! ᕎੱխࣝࣝभޑ໒วǺவΓᜪ೷Ո༸ಒझ຾ՉᐋँރಒझᡏѦคՈమ
ቚ෗ᇨᏤמೌϐࣴว 
р୯Γ঩
ۉӜ! ࠴Ͽঐ 
୍ܺᐒᄬ
Ϸᙍᆀ 
ϡඵεᏢ ϯᏢπำᆶ׷਑ࣽᏢس 
շ౛௲௤ 
཮᝼ਔ໔! 99ԃ 6Д 16ВԿ 
99ԃ 6Д 19В ཮᝼Ӧᗺ ऍ୯уԀᙑߎξ 
཮᝼Ӝᆀ!
(ύЎ)ಃΖۛ୯ሞ༸ಒझᏢ཮ԃ཮ 
(मЎ) International Society for Stem Cell Research 8th Annual Meeting 
ว߄ፕЎ
ᚒҞ!
(ύЎ) 
(मЎ) Characterization and large generation of functional dendritic cells 
from serum free expanded human cord blood CD34+ cells 
ߕҹѤ 
΋ǵୖу཮᝼࿶ၸ!
ϞԃಃΖۛ International Society for Stem Cell Research Annual MeetingᖐᒤӦᗺࣁ
ऍ୯ᙑߎξǴВයࣁ 2010ԃ 6Д 16ВԿ 19ВǴୖуΓኧऊ 3000ΓǶε཮ϣ৒хࡴಒ
झᆶಔᙃޑຑ՗ǵ୷Ӣݯᕍǵխࣝݯᕍǵ೷Ո༸ಒझǵߚՈన༸ಒझ(໔ယ༸ಒझ)ǵک
ჴᡍ࠻ᆶᙴଣޑೕጄ฻᝼ᚒǴᕴӅԖऊ 20ঁε཮ޑ workshopǵ10ঁቷ୘ޑ workshopǵ
8ঁ plenary sessionǵ100ጇαᓐፕЎൔ֋ᆶຬၸ 500ጇੇൔፕЎൔ֋Ǵϣ৒ཱུࣁᙦ൤Ƕ
җܭ೚ӭԖᑫ፪ک࣬ᜢϐ᝼ᚒӧӕ΋ਔࢤǵόӕ཮᝼࠻ᖐՉǴѸ໪٣Ӄᒧۓୖуϐ᝼ᚒ
 1
 3
CellǴϞԃޑ impact factorࣁ 24ᗺӭǶ 
 ૟൩ୖу೭ԛ཮᝼ޑӚЬाϣ৒຾Չख़ᗺޑඔॊǺ 
1. ဍዦ༸ಒझ(cancer stem cell)Ǻ 
ӧᕎੱ༸ಒझޑЬᚒ૸ፕύǴЬाԖѤঁᚒҞ຾Չ૸ፕǴځᚒҞᆶϣ৒ϩձ᏾౛ӵΠǺ 
(1) Breast cancer stem cells 
(2) Mechanism of drug resistance in cancer cells: mutation or chromosomal alteration? 
(3) Biology of Micrometastasis with solid tumors 
(4) Stem cells in hematologic maligancies 
΋૓ԶقǴ҅தಔᙃϐ܌аૈᆢ࡭ځғ౛ࢲ܄ࣣࢂҗ΋ဂϿໆޑ༸ಒझόᘐޑ຾Չ
ϩ຋ᆶϩϯǴٰڗж૰Դޑಒझ٠ᆢ࡭၀ಔᙃфૈޑ҅தǶ߈ԃٰǴԖ೚ӭޑЎ᝘ൔᏤ
ࡰрǴӧဍዦύ߾Ӹӧ΋ဂڀԖ༸ಒझ੝܄ޑဍዦ༸ಒझ(Ҟ߻ςӧՈᕎǵઓ࿶ᕎǵ΢Ҝ
ಒझᕎᆶ٢ᕎ฻ဍዦύว౜)Ǵᙖҗόᘐޑϩ຋ᆶϩϯٰᘉεဍዦޑጄൎǴԶځдϩϯ҃
ᆄޑဍዦಒझǴനࡕஒᆶ΋૓҅தಒझӕኬޑ཮य़ᖏԴϯޑၸำԶԝΫǴ೭٤ჴᡍ΢ޑ
ว౜ᜬᙟΑ໺಍ޑᢀۺǴᇡࣁဍዦޑᘉεᆶғߏࢂҗ܌Ԗޑᕎಒझόᘐቚғ܌ᄬԋǴΨ
ගٮΑᕎੱݯᕍޑќ΋ᅿࡘᆢǴᆶ཮ᏢޣᇡࣁǴ΋૓ޑᕎੱϯᕍᛰނ஑΋܄եЪୋբҔ
εǴݯᕍޑၸำёૈఠԝε೽ϩޑဍዦಒझԶߚဍዦ༸ಒझǴ܌аӧᖏ׉ݯᕍޑ่݀
ࢂǴੰ஻ӧ࿶ၸϯᏢݯᕍࡕǴဍዦޑᡏᑈ཮ᕭλࣗԿ཮੃ѨόـǴՠࢂ೽ϩޑੰΓӧъ
ԃϐࡕǴဍዦ཮Ԗൺวޑ౜ຝǴཀښ๱౜Ԗޑϯᕍᛰނคݤ஑΋ޑఠԝဍዦ༸ಒझǴԜ
Ѧൺวޑဍዦ཮ౢғჹϐ߻ϯᕍᛰނޑלᛰ܄ǴᏤठ஻ޣӧဍዦൺวࡕǴזೲޑԝΫǴ
ӢԜӵՖפрဍዦ༸ಒझᆶ΋૓ဍዦಒझޑৡ౦Ǵ٠Ъ೛ीрڀԖଯ஑΋܄ࢥఠဍዦ༸
ಒझޑᛰނǴࢂࣁҞ߻ᖏ׉΢ന዗ߐޑፐᚒǶӕਔǴΨයࡑᙖҗဍዦ༸ಒझғ౛੝܄ޑ
௖૸Ǵ຾΋؁ᕕှဍዦಒझᙯ౽ޑᐒڋǴٰၲډߔЗဍዦᘉණޑҞޑǶ 
 
 5
ԋੰΓޑԝΫǴ၀ი໗ӧ౽෌ၸำύӕਔ౽෌໔ယ༸ಒझǴว౜ёаफ़եխࣝ௨Ѿޑϸ
ᔈǴᇡࣁ໔ယ༸ಒझޑӸӧǴԖշܭቚу౽෌ޑԋф౗Ƕ 
 
3. ୷Ӣݯᕍޑཥว৖(Novel developments in gene therapy)Ǻ 
ӧ୷Ӣݯᕍޑཥว৖ޑЬᚒ૸ፕύǴЬाԖΟঁᚒҞ຾Չ૸ፕǴځᚒҞᆶϣ৒ϩձ᏾౛
ӵΠǺ 
(1) Gene therapy using Hematopoietic stem cell: current status 
(2) Development of novel ZFP therapeutics for targeted gene modification: a new 
approach to gene therapy 
(3) Modification of hematopoietic cells with integrating gene vectors 
ӧᖏ׉ݯᕍ΢ǴճҔ౦ᡏ೷Ո༸ಒझ౽෌ٰၲډݯᕍᒪ໺܄ޑՈన੯ੰԖ๱ؼӳޑ
่݀Ǵཀښ๱ӵ݀ճҔԾᡏ೷Ո༸ಒझ౽෌у΢୷Ӣᕍݤٰݯᕍᒪ໺܄Ոన੯ੰ(ٯӵǺ
խࣝલഐ੯ੰᆶӭᅿ೦Ո฻)Ǵᔈ၀ΨૈԖ๱ؼӳޑ่݀ǶҞ߻ӧ୏ނ၂ᡍ΢٬Ҕޑ୷Ӣ
ᙯࢉπڀӭࣁੰࢥၩᡏǴЬाޑჹຝࣁխࣝόӄޑߚΓᜪᡫߏᜪᆶХࣽ୏ނǴճҔ
gamma-retrovial vector གࢉவ୏ނମᡎύڗளϐ೷Ո༸ಒझа຾Չ୷Ӣঅ҅ǴӧᡏѦ຾
Չቚ෗୻Ꭶࡕӆ౽෌Ε୏ނᡏϣǴԖ๱ܴᡉޑݯᕍ่݀Ƕӧಃ΋ٯޑΓᡏ၂ᡍБय़Ǵჹ
ຝࢂᒧ᏷஻Ԗ X-linked form of severe combined immune deficiencyޑ߃ғᓻٽǴஒ gamma 
common cytokine receptor gene ᙯ෗Εவ၀ᓻٽମᡎύڗрϐ CD34+ cellsǴӆஒಒझ౽෌
ӣᓻٽᡏϣǴ၀ᓻٽޑխࣝόӄ੯ੰளډׯ๓Ǵ٠ЪҞ߻၀ᓻٽς࿶ϖྃǶ߈ٰ߾Ԗᖏ
׉၂ᡍଞჹ஻Ԗ chronic granulomatous diseaseޑԋΓੰ஻ǴճҔ retrovial vectorஒ୷Ӣᙯ
෗ΕຼᜐՈనޑ೷Ո༸ಒझǴ่݀ว౜ૈ୼ԋфޑࡠൺੰΓޑלགࢉޑфૈǶҞ߻ςԖ
ӭঁӃ຾ޑ୯ৎӆ຾Չ୷ӢݯᕍޑΓᡏ၂ᡍǴݯᕍ੯ੰԖΠٯ൳ঁБӛǺ(1) ճҔ
Lentiviral vectorஒ globin geneᙯ෗ٰݯᕍआՈౚБय़ޑ੯ੰǹ(2) ୷Ӣፓ௓ Tಒझ߄य़
 7
િޑિެύ؂ 1 mlѳ֡ёаளډ 2.5 x 105ঁ໔ယ༸ಒझǴЪڀԖϩϯࣁઓ࿶ޑૈΚǴ٠
ЪڀԖ׭ڋխࣝϸᔈޑфૈǴӧ҂ٰஒ཮ࢂࡐӳޑ໔ယ༸ಒझٰྍǶѠ᡼୯ፁଣ߾ว߄
வजዬύϩᚆр໔ယ༸ಒझǴ੝܄ᆶ΢ॊޑ໔ယ༸ಒझ࣬՟Ƕ౲ӭჴᡍ᛾ܴǴΓᡏϣӭ
ೀࣣ֖Ԗ໔ယ༸ಒझǴӵՖפр֖ໆᙦ൤٠Ъڗள৒ܰޑ໔ယ༸ಒझǴஒࢂ҂ٰᖏ׉ᔈ
Ҕ΢ޑख़ाԵໆᗺϐ΋Ƕ 
 
5. ᙏ஥Ո(Cord blood)Ǻ 
ӧᙏ஥ՈޑЬᚒ૸ፕύǴЬाԖٿঁᚒҞ຾Չ૸ፕǴځᚒҞᆶϣ৒ϩձ᏾౛ӵΠǺ 
(1) Current results and future progress in cord blood transplant 
(2) Moving umbilical cord blood transplantation to adult patients 
Ծவ 1989ԃಃ΋ٯճҔᙏ஥Ո౽෌ٰݯᕍ Faconi’s anemiaԋфࡕǴԿϞςԖຬၸ
΋࿤ٯԋфޑ౽෌Ƕ߈ԃٰǴᙏ஥Ո೷Ո༸ಒझ౽෌ς೏ຎࣁගٮሡा౦ᡏ౽෌܈ࢂલ
Ю HLA-matched౽෌ٰྍޑ஻ޣǴќ΋ᅿёаԵቾޑ೷Ո༸ಒझٰྍǶճҔᙏ஥Ո౽෌
࣬ၨܭମᡎ౽෌ޑӳೀԖ(1)࣪ౣମᡎԏڗޑਔำǴёаග߻ 25-36ϺٮੰΓ౽෌ǹ(2)
ёаϢ೚ 1-2 HLA mismatchǹ(3)ၨեޑ GVHD௨Ѿϸᔈǹ(4)Ոనኬࠔޑեੰࢥགࢉ॥
ᓀ(ٯӵǺCMV܈ࢂ EBVޑགࢉ)ǹ(5)ჹܭਈᜄޣค໾্ǶฅԶᔈҔ΢നεޑ౟ᓍࢂᙏ
஥Ոύ܌֖೷Ո༸ಒझᕴኧໆόىǴᏤठ౽෌ࡕੰΓࡠൺೲࡋᄌǴቚу౽෌Ѩ௳ޑ॥
ᓀǶԜ᝼ำύЬा૸ፕޑࢂӵՖှ،΢ॊޑୢᚒǴБݤԖǺ(1)ᡏѦቚ෗ǹ(2)ӕਔ຾Չٿ
೓а΢ᙏ஥Ոޑ౽෌ǹ(3)ӕਔ౽෌໔ယ༸ಒझǹ(4)פ൨ගଯ೷Ո༸ಒझ homingૈΚޑ
Бݤ(ٯӵǺޔௗஒ೷Ո༸ಒझ౽෌Εମᡎύ)Ǵ٠᏾౛Ҟ߻΋٤Γᡏ܈ࢂ୏ނჴᡍޑ่
݀ǶԜѦ٠ԖᏢޣठΚܭ௖૸౽෌ࡕࡠൺޑႣෳࡰ኱ǴҞ߻ᖏ׉΢ࣣа CD34+ಒझޑኧ
ໆࣁႣෳࡰ኱Ǵՠࢂਔதว౜ᆶႣෳޑ่݀Ԗ܌ୃৡǴӢԜ཮ύගр΋٤Ӄว౜ޑࡰ
 9
ᡏ၂ᡍ΢ޑፏӭज़ڋǴ೷ԋѠ᡼ӧᔈҔቫय़΢ޑଶᅉό߻аठܭပࡕܭ୯ሞว৖ǴঁΓ
ሥࣁය೚୯ϣӃ຾ᆶଯቫǴࢂցૈࣁѠ᡼ғמғᙴౢ཰຾΋؁໒ബр׳Ԗճޑޜ໔Ǵٰ
٬Ѡ᡼όѝࢂӧႝηౢ཰΢Ǵӧғמғᙴౢ཰΢ΨૈԖሦᏤ୯ሞޑ΋ϺǶ 
!
ϖǵឫӣၗ਑ӜᆀϷϣ৒!
ឫӣ΋н Final program of 8th annual meeting of international society for stem cell 
researchǶ!
!
Ϥǵځд!
ว߄ፕЎᄔाᆶੇൔߕᒵӵࡕ।܌ҢǶ!
!
!
!
!
!
!
!
!
!
!
!
! 11

其他成果 
(無法以量化表達之成
果如辦理學術活動、獲
得獎項、重要國際合
作、研究成果國際影響
力及其他協助產業技
術發展之具體效益事
項等，請以文字敘述填
列。) 
無 
 成果項目 量化 名稱或內容性質簡述 
測驗工具(含質性與量性) 0  
課程/模組 0  
電腦及網路系統或工具 0  
教材 0  
舉辦之活動/競賽 0  
研討會/工作坊 0  
電子報、網站 0  
科 
教 
處 
計 
畫 
加 
填 
項 
目 計畫成果推廣之參與（閱聽）人數 0  
國科會補助專題研究計畫成果報告自評表 
請就研究內容與原計畫相符程度、達成預期目標情況、研究成果之學術或應用價
值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性）、是否適
合在學術期刊發表或申請專利、主要發現或其他有關價值等，作一綜合評估。
1. 請就研究內容與原計畫相符程度、達成預期目標情況作一綜合評估 
■達成目標 
□未達成目標（請說明，以 100字為限） 
□實驗失敗 
□因故實驗中斷 
□其他原因 
說明： 
2. 研究成果在學術期刊發表或申請專利等情形： 
論文：□已發表 ■未發表之文稿 □撰寫中 □無 
專利：□已獲得 □申請中 ■無 
技轉：□已技轉 □洽談中 ■無 
其他：（以 100字為限） 
3. 請依學術成就、技術創新、社會影響等方面，評估研究成果之學術或應用價
值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性）（以
500字為限） 
學術成就與創新：實驗結果證實，本研究已經的開發出適合樹突狀細胞於體外增殖培養的
培養基。實驗首先從臍帶血收集開始，進行造血幹細胞(CD34+細胞)的分離與純化，並經
由本所先前所開發之造血幹細胞無血清增殖培養基(SF-HSC)，增殖造血幹細胞一星期。接
著將增殖過後的造血幹細胞利用實驗設計與統計分析的方法，搭配著陡升路徑最適化細胞
激素濃度，證實增殖過後的造血幹細胞具有進一步分化為樹突狀細胞的能力，並且最適化
其培養基的組成及濃度。 
應用價值：(1) 結合先前開發之造血幹細胞增殖的技術，加上有系統的設計出樹突狀細胞
誘導培養基，能夠有效的大量培養出樹突狀細胞。(2) 低成本的高市場競爭力(細胞激素
的價格昂貴，而本系統的細胞激素配方濃度遠低於市面上的產品)，如此可以得到具有經
濟效益且成本較低的體外樹突狀細胞誘導培養基。(3) 快速的樹突狀細胞誘導技術更有利
於未來臨床上的使用。 
